Novo Nordisk A/S reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was DKK 48,092 million compared to DKK 38,333 million a year ago. Net income was DKK 13,592 million compared to DKK 10,892 million a year ago.

Basic earnings per share from continuing operations was DKK 3.015 compared to DKK 2.385 a year ago. Diluted earnings per share from continuing operations was DKK 3.01 compared to DKK 2.38 a year ago.